Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Strahlentherapie und Onkologie
Published in: Strahlentherapie und Onkologie 7/2019

01-07-2019 | Breast Cancer | Original Article

Influence of XRCC4 expression by breast cancer cells on ipsilateral recurrence after breast-conserving therapy

Authors: Mio Kitagawa, MD, Masanori Someya, MD, PhD, Tomokazu Hasegawa, MD, PhD, Toshihiko Mikami, MD, PhD, Kazuaki Asaishi, MD, PhD, Tadashi Hasegawa, MD, PhD, Yoshihisa Matsumoto, PhD, Goro Kutomi, MD, PhD, Ichiro Takemasa, MD, PhD, Koh-ichi Sakata, MD, PhD

Published in: Strahlentherapie und Onkologie | Issue 7/2019

Login to get access

Abstract

Background

We examined the expression of nonhomologous end-joining (NHEJ) proteins by breast cancer cells in patients with or without ipsilateral breast tumor recurrence (IBTR) after breast-conserving therapy. We also investigated whether there was a difference of NHEJ-related protein expression by tumor cells between two types of IBTR, i.e., true recurrence (TR) with regrowth from the tumor bed or development of a new primary tumor (NP).

Patients and methods

The original cohort comprised 560 breast cancer patients who received breast-conserving therapy between February 1995 and March 2006, including 520 patients without IBTR and 40 patients with IBTR. Propensity score matching was employed to select 40 trios (120 patients) consisting of 1 patient with IBTR and 2 patients without IBTR. Immunohistochemical examination of proteins related to NHEJ was performed in surgical specimens.

Results

The 40 patients with IBTR included 22 patients who developed TR and 18 who had NP. The 15-year overall survival rate was 85.9% for patients with NP and 95.5% for those with TR, while it was 96.5% for patients without IBTR. Patients with high XRCC4 expression in tumor cells had significantly higher IBTR rates than those with low XRCC4 expression (P < 0.001). The frequency of TR was significantly higher in patients with high expression of XRCC4 than in those with low XRCC4 expression (p < 0.001). XRCC4 expression by tumor cells was not significantly related to development of NP.

Conclusion

IBTR due to TR may be related to low radiosensitivity of tumor cells, possibly related to high XRCC4 expression.
Appendix
Available only for authorised users
Literature
1.
Darby S, McGale P, Correa C et al (2011) Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomized trials. Lancet 378(9804):1707–1716CrossRefPubMed
2.
Wapnir IL, Anderson SJ, Mamounas EP et al (2009) Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials. J Clin Oncol 24(13):2028–2037CrossRef
3.
Oouchi A, Sakata K, Masuoka H et al (2009) The treatment outcome of patients undergoing breast-conserving therapy: the clinical role of postoperative radiotherapy. Breast Cancer 16(1):49–57CrossRefPubMed
4.
Yoshida T, Takei H, Kurosumi M et al (2010) True recurrences and new primary tumors have different clinical features in invasive breast cancer patients with ipsilateral breast tumor relapse after breast-conserving treatment. Breast J 16(2):127–133CrossRefPubMed
5.
Ishitobi M, Ohsumi S, Inaji H et al (2012) Ipsilateral breast tumor recurrence (IBTR) in patients with operable breast cancer who undergo breast-conserving treatment after receiving neoadjuvant chemotherapy: risk factors of IBTR and validation of the MD Anderson Prognostic Index. Cancer 118(18):4385–4393CrossRefPubMed
6.
Veronesi U, Marubini E, Del Vecchio M et al (1995) Local recurrences and distant metastases after conservative breast cancer treatments: partly independent events. J Natl Cancer Inst 87(1):19–27CrossRefPubMed
7.
Panet-Raymond V, Truong PT, McDonald RE et al (2011) True recurrence versus new primary: an analysis of ipsilateral breast tumor recurrences after breast-conserving therapy. Int J Radiat Oncol Biol Phys 81(2):409–417CrossRefPubMed
8.
Hall EJ (2006) DNA strand breaks and chromosomal aberrations. In: Hall EJ, Giaccia AM (eds) Radiobiology for the Radiologist, 6th edn. Lippincott Williams & Wilkins, Philadelphia, pp 16–29
9.
10.
Li Z, Otevrel T, Gao Y et al (1995) The XRCC4 gene encodes a novel protein involved in DNA double-strand break repair and V(D)J recombination. Cell 83(7):1079–1089CrossRefPubMed
11.
Bryans M, Valenzano MC, Stamato TD (1999) Absence of DNA ligase IV protein in XR-1 cells: evidence for stabilization by XRCC4. Mutat Res 433(1):53–58CrossRefPubMed
12.
Berg E, Christensen MO, Dalla RI et al (2011) XRCC4 controls nuclear import and distribution of Ligase IV and exchanges faster at damaged DNA in complex with Ligase IV. Dna Repair (Amst) 10(12):1232–1242CrossRef
13.
Iles N, Rulten S, El-Khamisy SF, Caldecott KW (2007) APLF (C2orf13) is a novel human protein involved in the cellular response to chromosomal DNA strand breaks. Mol Cell Biol 27(10):3793–3803CrossRefPubMedPubMedCentral
14.
Jeggo PA (1998) Identification of genes involved in repair of DNA double strand-breaks in mammalian cells. Radiat Res 150:S80–S91CrossRefPubMed
15.
Söderlund Leifler K, Queseth S, Fornander T et al (2010) Low expression of Ku70/80, but high expression of DNA-PKcs, predict good response to radiotherapy in early breast cancer. Int J Oncol 37(6):1547–1554PubMed
16.
Sakata K, Matsumoto Y, Tauchi H et al (2001) Expression of genes involved in repair of DNA double-strand breaks in normal and tumor tissues. Int J Radiat Oncol Biol Phys 49(1):161–167CrossRefPubMed
17.
Kamdar RP, Matsumoto Y (2010) Radiation-induced XRCC4 association with chromatin DNA analyzed by biochemical fractionation. J Radiat Res 51:303–313CrossRefPubMed
18.
Kanda Y (2013) Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant 48:452–458CrossRefPubMed
19.
Jobsen J, van der Palen J, Riemersma S et al (2014) Pattern of ipsilateral breast tumor recurrence after breast-conserving therapy. Int J Radiat Oncol Biol Phys 89(5):1006–1014CrossRefPubMed
20.
Sjöström M, Lundstedt D, Hartman L et al (2017) Response to radiotherapy after breast-conserving surgery in different breast cancer subtypes in the Swedish breast cancer group 91 radiotherapy randomized clinical trial. J Clin Oncol 35(28):3222–3229CrossRefPubMed
21.
della Rovere GQ, Benson JR (2002) Ipsilateral local recurrence of breast cancer: determinant or indicator of poor prognosis? Lancet Oncol 3(3):183–187CrossRefPubMed
22.
Gieni M, Avram R, Dickson L et al (2012) Local breast cancer recurrence after mastectomy and immediate breast reconstruction for invasive cancer: a meta-analysis. Breast 21(3):230–236CrossRefPubMed
23.
Schnitt SJ (2003) Risk factors for local recurrence in patients with invasive breast cancer and negative surgical margins of excision. Where are we and where are we going? Am J Clin Pathol 120(4):485–488CrossRefPubMed
24.
van der Leij F, Elkhuizen PH, Bartelink H et al (2012) Predictive factors for local recurrence in breast cancer. Semin Radiat Oncol 22(2):100–107CrossRefPubMed
25.
Hayashi J, Sakata KI, Someya M et al (2012) Analysis and results of Ku and XRCC4 expression in hypopharyngeal cancer tissues treated with chemoradiotherapy. Oncol Lett 4(1):151–155CrossRefPubMedPubMedCentral
26.
Hori M, Someya M, Sakata KI et al (2017) Influence of XRCC4 expression in esophageal cancer cells on the response to radiotherapy. Med Mol Morphol 50(1):25–33CrossRefPubMed
27.
Takada Y, Someya M, Sakata KI et al (2016) Influence of Ku86 and XRCC4 expression in uterine cervical cancer on the response to preoperative radiotherapy. Med Mol Morphol 49(4):210–216CrossRefPubMed
28.
29.
Metadata
Title
Influence of XRCC4 expression by breast cancer cells on ipsilateral recurrence after breast-conserving therapy
Authors
Mio Kitagawa, MD
Masanori Someya, MD, PhD
Tomokazu Hasegawa, MD, PhD
Toshihiko Mikami, MD, PhD
Kazuaki Asaishi, MD, PhD
Tadashi Hasegawa, MD, PhD
Yoshihisa Matsumoto, PhD
Goro Kutomi, MD, PhD
Ichiro Takemasa, MD, PhD
Koh-ichi Sakata, MD, PhD
Publication date
01-07-2019
Publisher
Springer Berlin Heidelberg
Published in
Strahlentherapie und Onkologie / Issue 7/2019
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-019-01468-z

Other articles of this Issue 7/2019

Strahlentherapie und Onkologie 7/2019 Go to the issue

Original Article

Long-term cosmetic outcome after preoperative radio-/chemotherapy in locally advanced breast cancer patients

Literatur kommentiert

Vitamin D und Omega-3-Fettsäuren senken das Risiko für Krebs und kardiovaskuläre Ereignisse nicht

Literatur kommentiert

Radiochirurgie und operative neurovaskuläre Dekompression annähernd gleichwertig bei der Behandlung von Trigeminusneuralgien

Original Article

Single-center long-term results from the randomized phase-3 TARGIT-A trial comparing intraoperative and whole-breast radiation therapy for early breast cancer

Original Article

Tomotherapy in malignant mesothelioma: a planning study to establish dose constraints

Literatur kommentiert

Durvalumab nach einer Radiochemotherapie ist beim NSCLC im Stadium III derzeit die vielversprechendste Therapie